Literature DB >> 23146620

Can inhA mutation predict ethionamide resistance?

V Vadwai1, K Ajbani, M Jose, V P Vineeth, C Nikam, M Deshmukh, A Shetty, R Soman, C Rodrigues.   

Abstract

SETTING: A tertiary care centre in Mumbai, India.
OBJECTIVE: To estimate the extent of association between inhA mutant isoniazid (INH) resistant strains and ethionamide (ETH) resistance.
DESIGN: A total of 140 clinical isolates processed for INH and ETH phenotypic drug susceptibility testing, and molecularly processed with the line-probe assay (LPA) Genotype® MTBDRplus, were considered.
RESULTS: Among the 112 phenotypically determined INH-resistant strains, 69 (61.6%) strains were ETH-resistant. An inhA promoter mutation was identified in 24 (21.4%) INH-resistant isolates, 21 (87.5%) of which were ETH-resistant (P < 0.0001).
CONCLUSION: An inhA promoter mutation could be considered as a marker for the determination of ETH resistance in India, where the use of LPA is being expanded.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146620     DOI: 10.5588/ijtld.12.0511

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.

Authors:  V R Bollela; E I Namburete; C S Feliciano; D Macheque; L H Harrison; J A Caminero
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

2.  Dilemmas with ethionamide susceptibility testing of Mycobacterium tuberculosis: A microbiologist & physician's nightmare.

Authors:  Mandira Varma-Basil; Rajendra Prasad
Journal:  Indian J Med Res       Date:  2015-11       Impact factor: 2.375

3.  Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain.

Authors:  Vegard Eldholm; Johana Monteserin; Adrien Rieux; Beatriz Lopez; Benjamin Sobkowiak; Viviana Ritacco; Francois Balloux
Journal:  Nat Commun       Date:  2015-05-11       Impact factor: 14.919

4.  Revisiting the susceptibility testing of Mycobacterium tuberculosis to ethionamide in solid culture medium.

Authors:  Rajagopalan Lakshmi; Ranjani Ramachandran; D Ravi Kumar; A Syam Sundar; G Radhika; Fathima Rahman; N Selvakumar; Vanaja Kumar
Journal:  Indian J Med Res       Date:  2015-11       Impact factor: 2.375

5.  Evaluation of GenoType MTBDRplus for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Karachi, Pakistan.

Authors:  Sara Siddiqui; Meredith B Brooks; Amyn A Malik; Junaid Fuad; Ahsana Nazish; Safia Bano; Mercedes C Becerra; Hamidah Hussain
Journal:  PLoS One       Date:  2019-08-19       Impact factor: 3.240

6.  Analysis of drug resistance and mutation profiles in Mycobacterium tuberculosis isolates in a surveillance site in Beijing, China.

Authors:  Jie Zhang; Yixuan Ren; Liping Pan; Junli Yi; Tong Guan; Xinyu Yang; Zongde Zhang
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

7.  The Value of the inhA Mutation Detection in Predicting Ethionamide Resistance Using Melting Curve Technology.

Authors:  Yanhua Song; Guirong Wang; Qiang Li; Rongmei Liu; Liping Ma; Qi Li; Mengqiu Gao
Journal:  Infect Drug Resist       Date:  2021-01-29       Impact factor: 4.003

8.  Correlation of inhA mutations and ethionamide susceptibility: Experience from national reference center for tuberculosis.

Authors:  Rohit Sarin; Manpreet Bhalla; Gavish Kumar; Anjali Singh; Vithal Prasad Myneedu; Ritu Singhal
Journal:  Lung India       Date:  2021 Nov-Dec

9.  Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.

Authors:  Karen R Jacobson; Marinus Barnard; Mary B Kleinman; Elizabeth M Streicher; Elizabeth J Ragan; Laura F White; Ofer Shapira; Tania Dolby; John Simpson; Lesley Scott; Wendy Stevens; Paul D van Helden; Annelies Van Rie; Robin M Warren
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.